EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the second quarter and first half of 2014. The company will host a conference call and webcast today at 8:30 a.m. EDT.
“We are pleased with the feedback from our pre-IND meeting last week for Recessive Dystrophic Epidermolysis Bullosa (RDEB),” said David Pernock, chairman and chief executive officer of Fibrocell. “We are excited to move forward with our animal studies at Stanford University which will lead to an IND submission in early 2015.”
Help employers find you! Check out all the jobs and post your resume.
